https://www.eurekalert.org/news-releases/937785
News Release 13-Dec-2021
Evidence review reveals little, if any, clinical benefit to drug that costs Medicare hundreds of millions of dollars annually
Peer-Reviewed Publication
Oregon Health & Science University
An extremely expensive drug used for multiple sclerosis and other autoimmune disorders provides very little, if any, clinical benefit, according to a new evidence review published today by physicians and researchers at Oregon Health & Science University and Oregon State University.
The review, published in the journal JAMA Internal Medicine, found the clinical benefit of the drug Acthar (rACTH) is quite low compared to less-expensive alternatives.
-----
No comments:
Post a Comment